Phase 1: 126, Phase 2: 70, Phase 3: 119, Other: 22
Eli Lilly has transformed its portfolio with two breakthrough platforms: GLP-1/GIP receptor agonists for obesity and diabetes (tirzepatide/Mounjaro, retatrutide, orforglipron) and targeted oncology (Verzenio/abemaciclib in breast cancer, Retevmo/selpercatinib for RET-altered cancers, Jaypirca/pirtobrutinib for B-cell malignancies). The obesity franchise is generating an unprecedented volume of Phase 3 trials across cardiometabolic, liver disease, sleep apnea, kidney disease, and other conditions. In immunology, Omvoh (mirikizumab) for IBD and Olumiant (baricitinib) expansions add breadth beyond oncology and metabolic disease.
- Obesity / metabolic disease (GLP-1/GIP)
- Oncology (breast, RET-altered, BTK)
- Immunology / IBD
- Diabetes
- Alzheimer's disease (donanemab)
- Mounjaro / Zepbound (tirzepatide) — GLP-1/GIP dual agonist
- Verzenio (abemaciclib) — CDK4/6 inhibitor, breast cancer
- Retevmo (selpercatinib) — RET inhibitor, NSCLC/thyroid/other
- Jaypirca (pirtobrutinib) — non-covalent BTK inhibitor
- Omvoh (mirikizumab) — IL-23p19, IBD
- Donanemab — anti-amyloid beta, Alzheimer's
Monitor the Eli Lilly pipeline daily
Get alerts when Eli Lilly registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Trials |
|---|---|
| Obesity | 64 |
| Healthy | 55 |
| Overweight | 49 |
| Alzheimer Disease | 16 |
| Type 2 Diabetes | 15 |
| Neoplasm Metastasis | 13 |
| Diabetes Mellitus, Type 2 | 11 |
| Overweight or Obesity | 9 |
Lilly's tirzepatide/GLP-1 platform is the fastest-growing new drug class in history by trial volume. Any company developing obesity, metabolic, or cardiorenal therapeutics needs close visibility into Lilly's expanding label trials. Their oncology pipeline (Verzenio combinations, Retevmo expansions) also generates consistent new Phase 2/3 registrations.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Eli Lilly's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Eli Lilly may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Eli Lilly pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With… NCT05614739 | Recruiting | Trial arms changed: 5 → 8 | 2026-08-21 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or… NCT05869903 | Active, Not Recruiting | Primary endpoint(s) modified | 2026-08-15 |
| A Study of LY4515100 in Healthy Participants NCT07339722 | Recruiting | Completion pushed: 2026-07 → 2027-03 | 2026-07-30 |
| A Platform Trial for Pediatric Participants With Obesity or Overweight… NCT06672549 | Recruiting | Trial sites expanded: 104 → 117 locations | 2026-08-25 |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major… NCT06292013 | Active, Not Recruiting | Trial sites reduced: 931 → 928 locations | 2026-08-25 |
Each trial page shows every change DataLookout has recorded for that trial.